When the NHS recognised ADHD in adults in 2008, never in my wildest hypochondriacal dreams did I imagine it applied to me. I ...
Start slow and go low” is a phrase in the cannabis industry about how to approach dosing. But nurses specializing in ...
A randomized, double-blind multicenter trial in Lancet HIV reported reductions in hepatic fat fraction in HIV-associated ...
Market valued at $72.4M in 2024, projected 7.30% CAGR growth driven by pharmaceutical API synthesis, food-grade ...
Nimbus Healthcare announced Nimbus Meals by Snap Kitchen, a 12-week program that integrates GLP-1 medication management with ...
Remote monitoring is increasing as new reimbursement paths open up. But even the best programs are no guarantee of success.
Hello! India on MSN
The future of slimming drugs in India, as told by an expert
GLP-1 drugs are shifting obesity from stigma to science. Dr. Kiran Sethi of Delhi-based clinic, Isyaderm, explains how these ...
Patients and physicians often both play a role when a patient’s treatment stalls. There are ways to prevent it.
Anavex Life Sciences (NASDAQ:AVXL) outlined its strategy to develop oral, precision-medicine therapies for central nervous ...
By reinforcing exercise, health care providers can ensure that GLP-1 therapy leads to weight loss, sustains muscle mass, and ...
Neurocrine Biosciences, Inc. today announced the presentation of the first head-to-head data comparing vesicular monoamine transporter 2 (VMAT2) target occupancy between INGREZZA® (valbenazine) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback